Global drug giant boosts Boulder biotech's funding round to $150 million
The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...
Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M
Sanofi invests in Enveda, reaffirming the industry’s confidence in its AI drug discovery platform and ability to deliver differentiated medicines.
Nature1y
Unlocking the natural world to search for new medicines
While many drug companies avoid targets deemed ‘undruggable’, US-based Enveda Biosciences attacks them head on. Founded in 2019, Enveda uses unique libraries and machine-learning technologies ...
Yahoo Finance26d
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda has since identified asthma as a high-impact follow-on indication for ENV-294 following promising preclinical and translational data in asthma models. This expansion underscores the company ...
UBS1y
Transforming nature into new medicines
That is, until now. India-based business, Enveda Biosciences, is mapping nature's chemistry and enabling the healthcare industry to rapidly discover, develop and deliver new drugs. The company is ...
Joplin Globe26d
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic ...